An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

Abstract

Background:

Historically, the Renal Unit at King’s College Hospital used intravenous (IV) iron sucrose (IS) to treat iron deficiency anaemia in patients with chronic kidney disease who were not on dialysis (CKD-ND). As part of a service initiative to improve patient experience, new products were considered as alternatives. This study investigated the potential impact on patient experience and service costs by switching from IS to ferric carboxymaltose (FCM).

Methods:

A decision analytical model was used to calculate the impact of switching from IS to FCM for a cohort of CKD-ND patients. Service provision data were collected for 365 patients who received 600 mg IS within a 12 month period, creating the IS data set. The service provision data, along with a clinically relevant FCM administration protocol (stipulating total doses of 500 mg FCM), were used to calculate a corresponding theoretical data set for FCM for the same cohort of patients.

Results:

The FCM protocol saved each patient two hospital visits and 2.66 hours of time (equating to approximately a saving of £36.21 in loss of earnings) and £19 in travel costs. Direct attributable costs for iron administration (which included drug, disposables, nursing staff, and hospital-provided patient transport costs) were £58,646 for IS vs £46,473 for FCM. Direct overhead costs (which included nursing preparation time, administration staff, clinic space, and consultant time costs) were £40,172 for the IS service vs £15,174 for the FCM service.

Limitations:

Based on clinical experience with the products, this analysis assumes that 500 mg FCM is therapeutically equivalent to 600 mg IS. Consultant time costs are assumed to be the same between the two treatment groups. IV iron administration protocols and data are specific to King’s College Hospital. The design is retrospective and changes to the management of the clinic, including service delivery optimization, may also affect real costs.

Conclusion:

FCM was associated with fewer hospital visits and reduced transport costs for CKD-ND patients receiving IV iron and has the potential to save 19–37% in service costs. Owing to increased administration efficiency, FCM can improve the overall patient experience while reducing the total cost of the King’s College Hospital IV iron service for CKD-ND patients, compared with treatment with IS.

Keywords::

• Iron
• Renal insufficiency (chronic)
• Ferric carboxymaltose
• Ferric oxide saccharated
• Healthcare costs
• Patient-centred care

Transparency

Declaration of funding

Data collection and analysis, and publication of the report was funded by Vifor Pharma Ltd. Vifor Pharma Ltd had no input into the editorial content of the paper.

Declaration of financial/other relationships

PW, IM, and AH have received sponsorship from Vifor Pharma. IM, AH, and AJ have all acted as a consult/advisor for Vifor Pharma. IM has also received grant/research funding from Vifor Pharma and is a member of the speakers bureau for Vifor Pharma. In addition, PW has received sponsorship from Janssen, has acted as a consult/advisor for Takeda and Evolution, and is a member of the Speakers Bureau for Hospira.

Acknowledgements

Editorial assistance was provided by Pope Woodhead and Associates Ltd, funded by Vifor Pharma.